Physician profile
Bethany Eubanks
NPI 1891302535
$903.88
in general payments reported to CMS, 2019-2025
12 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.88 · 2023: $183 · 2024: $259 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $140.44 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $137.48 | 2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Libtayo |
| Kite Pharma, INC. | $98.37 | 2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $95.88 | 2022 | |
| Gilead Sciences, INC. | $84.50 | 2023 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $76.18 | 2025 | |
| Merck Sharp & Dohme LLC | $48.86 | 2025 | Keytruda, Lynparza |
| Eisai INC. | $33.46 | 2025 | |
| Pharmacosmos Therapeutics INC. | $25.42 | 2025 | Monoferric |
| Novocure INC. | $20.79 | 2025 | Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals Lp | $20.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Eubanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.